The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis
Open accessAbstract
Background: Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is an increasingly recognized cause of heart failure in older individuals. We sought to characterize the natural history of ATTR-CM and compare outcomes and quality of life among patients with acquired and hereditary forms of the disease. Methods: We studied 711 patients with wild-type ATTR-CM, 205 with hereditary ATTR-CM associated with the V122I variant (V122I-hATTR-CM), and 118 with non-V122I-hATTR-CM at the UK National Amyloidosis Center between 2000 and 2017. Patients underwent prospective protocolized evaluations comprising assessment of cardiac parameters, functional status by 6-minute walk test, quality of life according to the Kansas City Cardiomyopathy Questionnaire, and survival. Hospital service usage pre- and postdiagnosis was established using English central health records in a subset of patients. Results: There was substantial diagnostic delay, with patients using hospital services a median (interquartile range) of 17 (9–27) times during the 3 years before diagnosis, by which time quality of life was poor; diagnosis of wild-type ATTR-CM was delayed >4 years after presentation with cardiac symptoms in 42% of cases. Patients with V122I-hATTR-CM were more impaired functionally ( P <0.001) and had worse measures of cardiac disease ( P <0.001) at the time of diagnosis, a greater decline in quality of life, and poorer survival ( P <0.001) in comparison with the other subgroups. Conclusions: ATTR-CM is an inexorably progressive and eventually fatal cardiomyopathy associated with poor quality of life. Diagnosis is often delayed for many years after symptoms develop. Improved awareness and wider use of recently validated diagnostic imaging methods are urgently required for patients to benefit from recent therapeutic developments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
Self-citationTafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
Maurer, M. S., Schwartz, J. H., Gundapaneni, B., Elliott, P. M., Merlini, G., Waddington-Cruz, M., Kristen, A. V., Grogan, M., Witteles, R., Damy, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805689 · Cited by 2,857
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
Gillmore, J. D., Maurer, M. S., Falk, R. H., Merlini, G., Damy, T., Dispenzieri, A., Wechalekar, A. D., Berk, J. L., Quarta, C. C., Grogan, M., et al. (2016) · Circulation · doi:10.1161/circulationaha.116.021612 · Cited by 2,081
Self-citationInotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
Benson, M. D., Waddington-Cruz, M., Berk, J. L., Polydefkis, M., Dyck, P. J., Wang, A. K., Planté-Bordeneuve, V., Barroso, F. A., Merlini, G., Obici, L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716793 · Cited by 1,452
Self-citationON THE BINDING OF CONGO RED BY AMYLOID
PUCHTLER, H., SWEAT, F., & LEVINE, M. (1962) · Journal of Histochemistry & Cytochemistry · doi:10.1177/10.3.355 · Cited by 1,128
Perugini, E., Guidalotti, P. L., Salvi, F., Cooke, R. M. T., Pettinato, C., Riva, L., Leone, O., Farsad, M., Ciliberti, P., Bacchi-Reggiani, L., et al. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.05.073 · Cited by 981
Vrana, J. A., Gamez, J. D., Madden, B. J., Theis, J. D., Bergen, H. R., & Dogan, A. (2009) · Blood · doi:10.1182/blood-2009-07-230722 · Cited by 904
Systemic Cardiac Amyloidoses: Disease Profiles and Clinical Courses of the 3 Main Types
Rapezzi, C., Merlini, G., Quarta, C. C., Riva, L., Longhi, S., Leone, O., Salvi, F., Ciliberti, P., Pastorelli, F., Biagini, E., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.843334 · Cited by 774
Self-citationTanskanen, M., Peuralinna, T., Polvikoski, T., Notkola, I., Sulkava, R., Hardy, J., Singleton, A., Kiuru‐Enari, S., Paetau, A., Tienari, P. J., et al. (2008) · Annals of Medicine · doi:10.1080/07853890701842988 · Cited by 591
Frequency and distribution of senile cardiovascular amyloid
Cornwell, G. G., Murdoch, W. L., Kyle, R. A., Westermark, P., & Pitkänen, P. (1983) · The American Journal of Medicine · doi:10.1016/0002-9343(83)90443-6 · Cited by 483
Cited by
Kittleson, M. M., Maurer, M. S., Ambardekar, A. V., Bullock-Palmer, R. P., Chang, P. P., Eisen, H. J., Nair, A. P., Nativi-Nicolau, J., Ruberg, F. L., & On behalf of the American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology (2020) · Circulation · doi:10.1161/cir.0000000000000792 · Cited by 756
Kittleson, M. M., Ruberg, F. L., Ambardekar, A. V., Brannagan, T. H., Cheng, R. K., Clarke, J. O., Dember, L. M., Frantz, J. G., Hershberger, R. E., Maurer, M. S., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.11.022 · Cited by 640
Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis
Maurer, M. S., Kale, P., Fontana, M., Berk, J. L., Grogan, M., Gustafsson, F., Hung, R. R., Gottlieb, R. L., Damy, T., González-Duarte, A., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2300757 · Cited by 339
Self-citationHahn, V. S., Yanek, L. R., Vaishnav, J., Ying, W., Vaidya, D., Lee, Y. Z. J., Riley, S. J., Subramanya, V., Brown, E. E., Hopkins, C. D., et al. (2020) · JACC: Heart Failure · doi:10.1016/j.jchf.2020.04.007 · Cited by 306
Cardiac Scintigraphy With Technetium-99m-Labeled Bone-Seeking Tracers for Suspected Amyloidosis
Hanna, M., Ruberg, F. L., Maurer, M. S., Dispenzieri, A., Dorbala, S., Falk, R. H., Hoffman, J., Jaber, W., Soman, P., Witteles, R. M., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.04.022 · Cited by 255
Metadata
- Authors
- Lane, T., Fontana, M., Martinez-Naharro, A., Quarta, C. C., Whelan, C. J., Petrie, A., Rowczenio, D. M., Gilbertson, J. A., Hutt, D. F., Rezk, T., Strehina, S. G., Caringal-Galima, J., Manwani, R., Sharpley, F. A., Wechalekar, A. D., Lachmann, H. J., Mahmood, S., Sachchithanantham, S., Drage, E. P. S., Jenner, H. D., McDonald, R., Bertolli, O., Calleja, A., Hawkins, P. N., & Gillmore, J. D.
- Venue
- Circulation
- Published
- 2019-07-02
- Volume
- 140
- Issue
- 1
- Pages
- 16-26
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2944922806
- Cited by
- 535
- References
- 22
- FWCI
- 14.25
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis. https://app.cochat.ai/papers/10.1161/circulationaha.118.038169
- The paper
- Lane, T., Fontana, M., Martinez-Naharro, A., Quarta, C. C., Whelan, C. J., Petrie, A., Rowczenio, D. M., Gilbertson, J. A., Hutt, D. F., Rezk, T., Strehina, S. G., Caringal-Galima, J., Manwani, R., Sharpley, F. A., Wechalekar, A. D., Lachmann, H. J., Mahmood, S., Sachchithanantham, S., Drage, E. P. S., . . . Gillmore, J. D. (2019). Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis. Circulation. https://doi.org/10.1161/circulationaha.118.038169
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.